Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation - 'Beyond the TAP study'

Eye

Volumn 18, Issue 8, 2004, Pages 809-813

  Barnes, R M ^a   Gee, L ^a   Taylor, S ^a   Briggs, M C ^a   Harding, Simon P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Choroidal neovascularisation; Photodynamic therapy; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; FLUORESCEIN;

ARTICLE; CLINICAL PROTOCOL; CONTRAST SENSITIVITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; EYE REFRACTION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEALTH CARE DELIVERY; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MYOPIA; NATIONAL HEALTH SERVICE; PHOTODYNAMIC THERAPY; PUBLICATION; RECURRENT DISEASE; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; STEREORADIOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 4444250849     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701329     Document Type: Article

References (14)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-943.
2. Vingerling JR, Dielemans I, Hofman A et al. The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 1995; 102: 205-210.
3. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32: 375-413.
4. TAP study group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomised clinical trials. TAP report. Arch Ophthalmol 1999; 117: 1239-1245.
5. TAP study group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials. TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
6. VIP study group. Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two-year results of a randomised clinical trial including lesions with occult with no classic choroidal neovascularisation - verteporfin in photodynamic therapy report. Am J Ophthalmol 2001; 131: 541-560.
7. VIP study group. Photodynamic therapy of subfoveal choroidal neovascularisation in pathologic myopia with verteporfin: one-year results of a randomised clinical trial - VIP report no.. Ophthalmology 2001; 108(5): 841-852.
8. Harding SP. Verteporfin photodynamic therapy in the UK: implications of the NICE appraisal. Eye 2003; 17: 119-122.
9. National Institute for Clinical Excellence. Final appraisal determination: photodynamic therapy for age-related macular degeneration. http://www.nice.org.uk/Docref.asp?d=5410. Accessed 25-05-2003.
10. Harding SP. Photodynamic Therapy in the Treatment of Subfoveal Choroidal Neovascularisation. Eye 2001; 15: 407-412.
11. Early Treatment Diabetic Retinopathy Study Research Group. Early treatment diabetic retinopathy study design and baseline patient characteristics: ETDRS Report Number. Ophthalmology 1991; 98: 741-756.
12. Macular Photocoagulation Study. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthamol 1982; 100: 912-918.
13. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired vision equate with visual disability? Br J Ophthalmol 2000; 84: 244-250.
14. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108: 2051-2059.